Evidence map›Paper›PMID 38532435›Full record

ArticleSubstance abuse treatment, prevention, and policy2024

Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study.

Karl Trygve Druckrey-Fiskaaen, Jørn Henrik Vold, Tesfaye Madebo, Håvard Midgard, Olav Dalgard, Rafael Alexander Leiva, Lars T Fadnes, INTRO-HCV Study Group

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Karl Trygve Druckrey-FiskaaenBergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway. karl.fiskaaen@uib.no.
Jørn Henrik VoldBergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Tesfaye MadeboBergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
Håvard MidgardDepartment of Gastroenterology, Oslo University Hospital, Oslo, Norway.
Olav DalgardDepartment of Infectious Diseases, Akershus University Hospital, Lørenskog, Norway.
Rafael Alexander LeivaDepartment of Infectious Diseases, Haukeland University Hospital, Bergen, Norway.
Lars T FadnesBergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
INTRO-HCV Study Group
Haukeland University Hospital · NOAkershus University Hospital · NOOslo University Hospital · NOStavanger University Hospital · NOUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersons with opioid use disorders (OUD) and persons with substance use disorders (SUD) who inject substances have a reduced life expectancy of up to 25 years compared with the general population. Chronic liver diseases are a substantial cause of this. Screening strategies based on liver stiffness measurements (LSM) may facilitate early detection, timely intervention, and treatment of liver disease. This study aims to investigate the extent of chronic liver disease measured with transient elastography and the association between LSM and various risk factors, including substance use patterns, hepatitis C virus (HCV) infection, alcohol use, body mass index, age, type 2 diabetes mellitus, and high-density lipoprotein (HDL) cholesterol among people with OUD or with SUD who inject substances.

methodsData was collected from May 2017 to March 2022 in a cohort of 676 persons from Western Norway. The cohort was recruited from two populations: Persons receiving opioid agonist therapy (OAT) (81% of the sample) or persons with SUD injecting substances but not receiving OAT. All participants were assessed at least once with transient elastography. A linear mixed model was performed to assess the impact of risk factors such as HCV infection, alcohol use, lifestyle-associated factors, and substance use on liver stiffness at baseline and over time. Baseline was defined as the time of the first liver stiffness measurement. The results are presented as coefficients (in kilopascal (kPa)) with 95% confidence intervals (CI).

resultsAt baseline, 12% (n = 83) of the study sample had LSM suggestive of advanced chronic liver disease (LSM ≥ 10 kPa). Advanced age (1.0 kPa per 10 years increments, 95% CI: 0.68;1.3), at least weekly alcohol use (1.3, 0.47;2.1), HCV infection (1.2, 0.55;1.9), low HDL cholesterol level (1.4, 0.64;2.2), and higher body mass index (0.25 per increasing unit, 0.17;0.32) were all significantly associated with higher LSM at baseline. Compared with persistent chronic HCV infection, a resolved HCV infection predicted a yearly reduction of LSM (-0.73, -1.3;-0.21) from baseline to the following liver stiffness measurement.

conclusionsMore than one-tenth of the participants in this study had LSM suggestive of advanced chronic liver disease. It underscores the need for addressing HCV infection and reducing lifestyle-related liver risk factors, such as metabolic health factors and alcohol consumption, to prevent the advancement of liver fibrosis or cirrhosis in this particular population.

Indexed as

Diabetes Mellitus, Type 2Hepatitis CHepatitis C, ChronicSubstance-Related DisordersChildHumansLiverLiver CirrhosisProspective StudiesRisk FactorsChronic liver diseaseElastographyHepatitis CInjecting drug useLiver stiffness measurementOpioid agonist treatmentProspective cohortSteatotic liver diseaseSubstance use disorder

Identifiers

PMID38532435
PMCPMC10964694
OpenAlexW4393191720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.